NEW YORK, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Catalent, Inc. ("Catalent" or the "Company") (NASDAQ:CTLT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
The investigation concerns whether Catalent and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
[Click here for information about joining the class action]
On February 5, 2024, Catalent announced that it had agreed to be sold to Novo Holdings for $63.50 per share in cash. Novo Holdings is the controlling shareholder of the Novo Group companies (including Novo Nordisk), and ...